Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Lifts Clinical Hold On Dynavax's Hep B Vaccine Heplisav, Narrows Population

This article was originally published in The Pink Sheet Daily

Executive Summary

The firm is hoping to gain licensure for chronic kidney disease patients first, and eventually to expand the indication to the broader hepatitis B vaccination population.

Related Content

Dynavax Hep B Vaccine Gets Second Panel Review; Scrutiny On Safety, Superiority
Adjuvants Need Approval Pathway Separate From Vaccines, Industry Tells FDA
FDA Still Not Comfortable With New Vaccine Adjuvants, Industry Veterans Say
Pfizer TLR-9 Adjuvant With Prevnar In HIV Patients Hints At Post-Wyeth Vaccine Opportunities
GSK Cervarix Clears Landmark FDA Vaccine Committee with Okay for Novel Adjuvant
Adjuvanted H1N1 Vaccine Excites FDA Panel, But Jury Is Still Out
Merck Returns Heplisav To Dynavax After FDA Rules Vaccine Too Risky For Healthy Adults
Merck’s Heplisav Gets FDA Clinical Hold
Merck’s Heplisav Gets FDA Clinical Hold
Dynavax Licenses Coley’s Toll-Like Receptor Adjuvant For Hep B Vaccine Candidate Heplisav





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts